Targeting the intratumor heterogeneity in PMBL

Cell Cycle. 2014;13(15):2317-8. doi: 10.4161/cc.29828.
No abstract available

Keywords: BCL6; immunochemotherapy; oncogenic programs; pSTAT6; sensitization.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Genetic Heterogeneity*
  • Humans
  • Lymphoma, B-Cell / genetics*
  • Lymphoma, B-Cell / therapy*
  • Mediastinal Neoplasms / genetics*
  • Mediastinal Neoplasms / therapy*
  • Oncogenes*
  • Prednisone / therapeutic use
  • Rituximab
  • Secondary Prevention
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone